

ASSISTING PHYSICIANS IN TREATING PATIENTS WITH OPIOID DEPENDENCY

The Recovery Platform,
available through LabCorp[†]

Allowing for seamless integration to LabCorp's medication-assisted treatment (MAT) monitoring services, The Recovery Platform's software supports compliance with MAT and helps patients stay on track with their recovery.

The Recovery Platform software is a digital electronic health record plug-in designed to monitor the progress of opioid-use disorder (OUD) recovery through a patient compliance dashboard and integrated digital capabilities. It includes key features to help physicians adhere to Substance Abuse and Mental Health Services Administration (SAMHSA) requirements* in order to continue prescribing Suboxone[®] as part of MAT for opioid use disorder, including:

- Controlled Substance Database Check
- Randomized Lab Testing
- Integrated LabCorp Results
- Counseling Capability
- Digital Notes
- Virtual Visit Capability
- EMR Connectivity
- Compliance dashboard

*Note: in order to maintain a Suboxone/buprenorphine waiver, physicians must meet SAMHSA requirements including review of the state-controlled substance database¹, randomized urine drug testing¹, and the capability to refer patients to counseling².

[†]Physicians will have a separate service agreement with The Recovery Platform.

LabCorp is a full-service laboratory that provides exceptional customer service, patient care, and consultative technical expertise:

- Exclusive national laboratory integrated within The Recovery Platform
- Comprehensive test menu, including: Suboxone[®] medication assisted treatment test options, LabCorp MedWatch[®] test options, and comorbidity and core clinical testing
- Extensive managed care network
- Technical support hotline

Recovery Platform



Example of Compliance Dashboard
Bringing Compliance to Recovery

LabCorp is a Full Service Laboratory for Suboxone® Providers

In an effort to address the opioid crisis, LabCorp has developed several test options to help manage Suboxone® medication assisted treatment for opioid dependent patients.

LabCorp offers individual and profile test options, including the medication assisted treatment monitoring profiles listed below. Physicians should only order those tests necessary to make individualized patient treatment. Only one test option should be ordered per patient per date of service.

	Buprenorphine Medication Assisted Treatment Screen Only, Urine	Buprenorphine Medication Assisted Treatment Monitoring 1, Urine	Buprenorphine Medication Assisted Treatment Monitoring 2, Urine
Test No	701385	701486	701330
Norbuprenorphine/ Buprenorphine Ratio	No	Yes (if buprenorphine positive)	Yes (if buprenorphine positive)
Test Methodology	IA Screen Only	IA Screen, reflex to buprenorphine MS confirm	IA Screen, reflex to MS confirm
CPT Code(s)	80307	80307; addtl 80348 & 80362 if reflex to confirm	80307; addtl CPT if reflex to confirm
Specimen	30 mL random urine	30 mL random urine	30 mL random urine
Container	Urine container	Urine container	Urine container
Total Drug Classes Included	15	15	18
Total Drug Metabolites Included	N/A	3, if buprenorphine positive	51
Specimen Validity Testing	Creatinine, pH	Creatinine, pH	Creatinine, pH, Nitrites
Drug/Drug Classes Included			
Alcohol Biomarkers (EtG, EtS)	+	+	+
Amphetamines	+	+	+ (incl. methamphetamines)
d/l methamphetamines			If methamphetamines positive
Barbiturates	+	+	+
Benzodiazepines	+	+	+
Buprenorphine	+	+	+
Cannabinoid (THC)	+	+	+
Cocaine	+	+	+
Fentanyl			+
Methadone	+	+	+
Naloxone		If buprenorphine positive	If buprenorphine positive
Opiates	+	+	+
Heroin Metabolite (6-AM)	+	+	+
Oxycodone/ Oxymorphone	+	+	+
Phencyclidine	+	+	+
Propoxyphene	+	+	+
Tapentadol	+	+	+
Tramadol	+	+	+
Carisoprodol			+
Gabapentin			+

Urine drug testing is a critical component in patient care for monitoring treatment compliance and may help achieve optimal outcomes when used in conjunction with patient risk assessment. Laboratory testing that is not considered medically necessary may result in coverage denials.

References:

1. U.S. Department of Health and Human Services: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Medications for opioid use disorder: a treatment improvement protocol Tip 63. Rockville, Maryland: 2018. DHHS Publication No. (SMA) 18-5063FULLDOC.
2. Qualifying for a physician waiver <http://samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/qualify-for-physician-waiver>, accessed October 11, 2017.

For additional information about The Recovery Platform, please contact your LabCorp Sales Representative or visit LabCorp.com/TheRecoveryPlatform.

For more information about LabCorp test options, please contact your LabCorp representative, or consult the [LabCorp Test Menu](http://www.labcorp.com) at www.labcorp.com



www.LabCorp.com